Department of Biology, Faculty of Basic Sciences, Islamic Azad University, Garmsar branch, Semnan, Iran.
Psychopharmacology (Berl). 2013 Jun;227(3):553-66. doi: 10.1007/s00213-013-2987-y. Epub 2013 Feb 13.
Numerous investigations have indicated that hepatic encephalopathy (HE) alters the levels of various neurotransmitters. However, comprehensive data regarding the effects of CA1 opioidergic and dopaminergic (DAergic) systems on HE-induced amnesia are still lacking.
Following intra-dorsal hippocampal (CA1) injection of mu opioid and dopamine D1- and D2-like receptors antagonists in male mice, one-trial step-down and hole-board paradigms were used to assess memory and exploratory behaviors, respectively.
Our data demonstrated that HE impairs memory 24 days after bile duct ligation (BDL). Furthermore, while the higher dose of DA D1-like receptor antagonist (SCH23390, 0.5 μg/mouse) induced amnesia and anxiogenic-like behaviors, mu receptor antagonist (naloxone: 0.0125, 0.025 and 0.05 μg/mouse) and DA D2-like receptor antagonist (sulpiride: 0.0625, 0.125 and 0.25 μg/mouse) by themselves, could not exert an effect on memory performance in passive avoidance task. On the other hand, pre-test injection of all drugs reversed the HE-induced amnesia 24 days after BDL, while having no effect on exploratory behaviors. Pre-test co-administration of the subthreshold dose SCH23390 (0.25 μg/mouse) and sulpiride (0.0625 μg/mouse) or naloxone (0.0125 μg/mouse) could likewise reverse the BDL-induced amnesia. However, when the subthreshold sulpiride plus naloxone were co-administered, BDL-induced amnesia was not blocked.
Memory performance is impaired 24 days post BDL and CA1 mu opioid and DA D1-like receptors antagonist synergistic effects are likely involved in this phenomenon.
大量研究表明肝性脑病(HE)会改变各种神经递质的水平。然而,关于 CA1 阿片能和多巴胺(DA)能系统对 HE 诱导的健忘症的影响的综合数据仍然缺乏。
在雄性小鼠海马(CA1)背内注射μ阿片和多巴胺 D1-和 D2-样受体拮抗剂后,使用单次台阶式下降和洞板范式分别评估记忆和探索行为。
我们的数据表明,胆总管结扎(BDL)后 24 天,HE 会损害记忆。此外,虽然较高剂量的 DA D1-样受体拮抗剂(SCH23390,0.5μg/只)会引起健忘症和焦虑样行为,但μ受体拮抗剂(纳洛酮:0.0125、0.025 和 0.05μg/只)和 DA D2-样受体拮抗剂(舒必利:0.0625、0.125 和 0.25μg/只)本身不会对被动回避任务中的记忆表现产生影响。另一方面,预测试注射所有药物均可逆转 BDL 后 24 天的 HE 诱导的健忘症,而对探索行为没有影响。预测试联合给予亚阈值剂量的 SCH23390(0.25μg/只)和舒必利(0.0625μg/只)或纳洛酮(0.0125μg/只)也可以逆转 BDL 诱导的健忘症。然而,当亚阈值舒必利加纳洛酮联合给药时,BDL 诱导的健忘症并未被阻断。
BDL 后 24 天记忆表现受损,CA1 阿片能和 DA D1-样受体拮抗剂的协同作用可能与此现象有关。